Keystone Symposia

Eldorado Hotel & Spa Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2020



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibodies as Drugs: From B Cell Biology to New Treatments (B1)


Organizer(s) Paul Carter, Janine Schuurman and Karl Dane Wittrup
February 2—6, 2020
Eldorado Hotel & Spa • Santa Fe, NM USA
Discounted Abstract Deadline: Oct 17, 2019
Abstract Deadline: Nov 5, 2019
Scholarship Deadline: Oct 17, 2019
Discounted Registration Deadline: Dec 5, 2019

Sponsored by BioLegend, Inc., Compass Therapeutics, Incyte Corporation, MorphoSys AG and Surface Oncology

Supported by a grant from Genentech

Summary of Meeting:
Since the mid-1990s, antibodies have grown steadily into a clinically important pharmaceutical class with over 70 antibody-based drugs approved, predominantly in oncology, autoimmunity and inflammation. As the antibody drug field has expanded and matured in recent years, the field has moved from empirical strategies to deep knowledge-based, designer approaches for which understanding of mechanisms of action is critical; there has also been a trend toward increasingly specialized meetings with a narrow focus such as cancer immunotherapy, bispecifics or B cell biology. In contrast, we are proposing a scientifically diverse program that spans a broad range of different and cutting-edge topics relevant to antibody drug development, including antibodies for infectious disease and antibody pharmacology, topics which are often under-represented at major antibody conferences. Additionally, we have chosen a diverse collection of speakers from junior investigators to seasoned researchers from a wide range of institutions in at least eight different countries. We hope and expect that this approach will stimulate ‘cross-pollination’ between disciplines that span the gamut from basic to translational to clinical sciences with the common theme of antibody drugs for the benefit of patients.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Sunday, February 2 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 6 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 7 in order to fully experience the meeting.

SUNDAY, FEBRUARY 2

4:00—8:00 PM
Arrival and Registration

Cava Santa Fe
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Cava Santa Fe

MONDAY, FEBRUARY 3

7:00—8:00 AM
Breakfast

Eldorado B
7:30—8:00 AM
Poster Setup

Eldorado B
8:00 AM—7:00 PM
Poster Viewing

Eldorado B
8:00—9:00 AM
Welcome and Keynote Address

Eldorado A
* Karl Dane Wittrup, Massachusetts Institute of Technology, USA

Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Future Prospects for Cancer Immunotherapy

9:00—11:15 AM
Immunoglobulin Repertoires: From Basic Biology to Therapeutic Applications

Eldorado A
* Laura M. Walker, Adimab LLC, USA

Pierre Bruhns, Institut Pasteur, France
Deep-Mining of Antibody Repertoires for Diagnostics and Therapeutic Antibody Discovery

Coffee Break

Ning Jenny Jiang, University of Texas at Austin, USA
Systems Immunology Based Immune Engineering

Sai T. Reddy, ETH Zurich, Switzerland
Antibody Discovery and Engineering by Deep Learning

Anupam Singhal, Berkeley Lights Inc., USA
Short Talk: Reaching the High-Hanging Fruit: Accessing Broad B Cell Diversity to Select Better Lead Candidates in Under 1 Week

11:15 AM—12:15 PM
Lunch

Eldorado B
12:00—2:30 PM
Poster Session 1

Eldorado B
4:30—5:00 PM
Coffee Available

Concourse
5:00—7:00 PM
Biology of Antibody Generation by B Cells

Eldorado A
* Pierre Bruhns, Institut Pasteur, France

Facundo D. Batista, Massachusetts Institute of Technology and Harvard University, USA
B Cell Activation: From Molecular Events to Antibody Production

Andrew Bradbury, Specifica, USA
Drug-Like Antibodies Straight From Selections: Enhanced Affinity & Developability from Specifica’s Generation 3 Platform

Shane Crotty, La Jolla Institute for Immunology, USA
Probing the Human Naive B Cell Repertoire, and Developing Immunization Strategies that Enhance Antibody and Germinal Center Responses via Modulation of Immunodominance

Patrick McTamney, AstraZeneca, USA
Short Talk: Utilizing the Human Body as a Bioreactor: Direct Comparison of in vivo Expressed Biologics (IVEB) Delivery Platforms

7:00 PM
On Own for Dinner


TUESDAY, FEBRUARY 4

7:00—8:00 AM
Breakfast

Eldorado B
8:00—11:00 AM
Advances in Antibodies for Immuno-Oncology

Eldorado A
* Falk Nimmerjahn, Universitätsklinikum Erlangen, Germany

Teemu T. Junttila, Genentech, Inc., USA
Optimization of Preclinical Safety and Efficacy of anti-HER2/CD3 TDB

Esther Breij, Genmab, Netherlands
Boosting Anti-Tumor Immunity using Bispecific Antibody Molecules

Coffee Break

Nicolas Fischer, Light Chain Bioscience / Novimmune SA, Switzerland
Harnessing Macrophage Activity via Targeted Inhibition of the CD47-SIPRa Axis

Jennifer E. O'Neil, Akrevia Therapeutics, USA
Development of a Highly Potent anti-CTLA-4 Antibody Active Specifically in the Tumor Microenvironment

Kamal Joshi, Genentech, Inc., USA
Short Talk: Probing Chain Pairing Preferences in Bispecific Antibodies to Facilitate Production in Single Host Cells

Susumu Uchiyama, Osaka University, Japan
Short Talk: Hydrogen/Deuterium Exchange Mass Spectrometry Analysis of Therapeutic IgG Molecules

11:00 AM—5:00 PM
On Own for Lunch

11:00 AM—1:00 PM
Poster Setup

Eldorado B
1:00—10:00 PM
Poster Viewing

Eldorado B
2:30—4:30 PM
Career Roundtable
Interested participants must sign up at the registration desk on a first-come, first-serve basis. Maximum attendance: 60.

Paul Carter, Genentech, Inc., USA

Laura M. Walker, Adimab LLC, USA

Ning Jenny Jiang, University of Texas at Austin, USA

Ana Maria Moro, Instituto Butantan, Brazil

Janine Schuurman, Genmab B.V., Netherlands

Sanjay Ram, University of Massachusetts, USA

4:30—5:00 PM
Coffee Available

Concourse
5:00—7:00 PM
Pharmacology of Antibody Drugs

Eldorado A
* Tomoyuki Igawa, Chugai Pharmabody Research, Singapore

Amrita Kamath, Genentech, Inc., USA
PK/PD Considerations for the Development of T-cell Dependent Bispecific Antibodies

Dhaval K. Shah, University at Buffalo, USA
Tissue Distribution of Antibodies: Pharmacokinetics/Pharmacodynamics Perspective

Tim Paul Hickling, Pfizer, Inc., USA
Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins

Rob N. de Jong, Genmab, Netherlands
Short Talk: Therapeutic IgG Antibody Combinations Acting as Bio-Logic AND Gates

David P. Humphreys, UCB Pharma, UK, UK
Short Talk: On Target Hexamerisation of IgG1 Driven by a Mutant Form of IgM tail-Piece C-Terminal Fusion

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Eldorado B
7:30—10:00 PM
Poster Session 2

Eldorado B

WEDNESDAY, FEBRUARY 5

7:00—8:00 AM
Breakfast

Eldorado B
8:00—11:15 AM
Antibody Effector Functions

Eldorado A
* Galit Alter, MIT and Harvard University, USA

Piet Gros, Utrecht University, Netherlands
Molecular Mechanisms of Antibody-Mediated Complement Activation

Leo James, MRC Laboratory of Molecular Biology, UK
Targeted Protein Depletion using Cytosolic Antibodies

Coffee Break

Falk Nimmerjahn, Universitätsklinikum Erlangen, Germany
The Organ Environment Determines Antibody-Dependent Immunotherapy Responses

Marjolein van Egmond, VU University Medical Center, Netherlands
IgA as Therapeutic Antibodies 2.0?

Stephanie Langel, Duke University, USA
Short Talk: Engineering Dimeric IgA Antibodies for Passive Transfer into Breastmilk and Protection against Human Rotavirus in Suckling Neonates

Irene Nailain Nkumama, Heidelberg University, Germany
Short Talk: Fc-Dependent Antibody Effector Functions Mediate Protective Immunity against Malaria

Yuki Yamaguchi, Osaka University, Japan
Short Talk: HDX-MS Analysis of IgG-FcRIII Interaction

11:15 AM—5:00 PM
On Own for Lunch

4:30—5:00 PM
Coffee Available

Concourse
5:00—7:00 PM
T Cell Targeting for Cancer Therapy

Eldorado A
* Esther Breij, Genmab, Netherlands

Thorbald van Hall, Leiden University Medical Center, Netherlands
CD3-Engagement in the Tumor Microenvironment

Tara Lynn Arvedson, Amgen Inc., USA
Targeting T Cells to Solid Tumors using BiTE® Molecules

Amir Alpert, Immatics Biotechnologies, USA
TCR-Based Cancer Immunotherapies to Novel pMHC

Ryan Molony, Novartis Institutes for Biomedical Research, USA
Short Talk: CD8+ T Cells Require CD4+ T Cell Help to Achieve Sustained in vitro Target Tumor Cell Killing Mediated by a CD3-Engaging Bispecific Antibody

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Eldorado B

THURSDAY, FEBRUARY 6

7:00—8:00 AM
Breakfast

Eldorado B
8:00—11:00 AM
Antibodies for the Treatment of Infectious Diseases

Eldorado A
* Sai T. Reddy, ETH Zurich, Switzerland

Laura M. Walker, Adimab LLC, USA
Longitudinal Dynamics of the Human B Cell Response to the Yellow Fever 17D Vaccine

Sanjay Ram, University of Massachusetts, USA
DNA-Encoded Anti-Lipooligosaccharide Monoclonal Antibody Engineered to Enhance Complement Activation as a Vaccination Strategy against Multidrug-Resistant Gonorrhea

Coffee Break

Joseph R. Francica, Vaccine Research Center, National Institutes of Health, USA
A Human Monoclonal Antibody Prevents Malaria Infection by Targeting Sporozoites in the Skin and Liver

Galit Alter, MIT and Harvard University, USA
A Systems Fc-Engineering Approach to Define Functional Humoral Correlates of Immunity

Raymond A. Alvarez, Ichor Biologics, USA
Short Talk: The Development of Human Monoclonal Antibodies to Treat Andes Hantavirus Infections

11:00 AM—5:00 PM
On Own for Lunch

4:30—5:00 PM
Coffee Available

Concourse
5:00—6:45 PM
Emerging Antibody Drugs for Neurodegenerative, Cardiovascular and Immunological Diseases

Eldorado A
* Marjolein van Egmond, VU University Medical Center, Netherlands

Tina Schwabe, Alector, USA
Immune Modulatory Antibody Drugs for Dementia

Tomoyuki Igawa, Chugai Pharmabody Research, Singapore
Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors

Jamie M. Orengo, Regeneron Pharmaceuticals Inc., USA
Novel Approaches to Treating Allergic Disorders with Monoclonal Antibodies

6:45—7:00 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Eldorado A
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Eldorado B
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Eldorado B

FRIDAY, FEBRUARY 7

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

BioLegend, Inc. Compass Therapeutics
Genentech, Inc. Incyte Corporation
MorphoSys AG Surface Oncology

We gratefully acknowledge additional support from these exhibitors at this conference:

10x Genomics
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge additional support for this conference from:

AdipoGen Life Sciences American Association for Cancer Research (AACR)
American Society of Gene & Cell Therapy (ASGCT) MacroGenics, Inc.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Adimab, Inc.


Akrevia Therapeutics


Genentech, Inc.


Genmab A/S


Immatics Biotechnologies GmbH


Light Chain Bioscience


Regeneron Pharmaceuticals, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179